Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Major Shareholder Sells $33,317.70 in Stock

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) major shareholder Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $0.10, for a total value of $33,317.70. Following the completion of the transaction, the insider now directly owns 9,900,000 shares in the company, valued at $990,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ltd Nirland also recently made the following trade(s):

• On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.12, for a total transaction of $122,018.76.

Conduit Pharmaceuticals Price Performance

NASDAQ:CDT opened at $0.10 on Friday. Conduit Pharmaceuticals Inc. has a 12 month low of $0.10 and a 12 month high of $7.83. The business’s 50-day moving average is $0.15 and its two-hundred day moving average is $1.56.

Conduit Pharmaceuticals (NASDAQ:CDT) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.07) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.